JP2020510091A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510091A5 JP2020510091A5 JP2019571788A JP2019571788A JP2020510091A5 JP 2020510091 A5 JP2020510091 A5 JP 2020510091A5 JP 2019571788 A JP2019571788 A JP 2019571788A JP 2019571788 A JP2019571788 A JP 2019571788A JP 2020510091 A5 JP2020510091 A5 JP 2020510091A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- solvate
- hydrate
- aryl
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C(*)(*)C(*)(*)C(*)(*)*C(N(*)*)=O Chemical compound *C(*)(*)C(*)(*)C(*)(*)*C(N(*)*)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1704327.4A GB201704327D0 (en) | 2017-03-17 | 2017-03-17 | Compounds |
| GB1704327.4 | 2017-03-17 | ||
| PCT/EP2018/056663 WO2018167269A1 (en) | 2017-03-17 | 2018-03-16 | Compounds useful in the treatment or prevention of a prmt5-mediated disorder |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020510091A JP2020510091A (ja) | 2020-04-02 |
| JP2020510091A5 true JP2020510091A5 (OSRAM) | 2021-04-30 |
| JP7211982B2 JP7211982B2 (ja) | 2023-01-24 |
Family
ID=58688233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019571788A Active JP7211982B2 (ja) | 2017-03-17 | 2018-03-16 | Ｐｒｍｔ５媒介性障害の治療又は予防に有用な化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11485731B2 (OSRAM) |
| EP (1) | EP3596061B1 (OSRAM) |
| JP (1) | JP7211982B2 (OSRAM) |
| KR (1) | KR102616970B1 (OSRAM) |
| CN (1) | CN110650950B (OSRAM) |
| AU (2) | AU2018235139A1 (OSRAM) |
| CA (1) | CA3056724A1 (OSRAM) |
| GB (1) | GB201704327D0 (OSRAM) |
| IL (1) | IL269354B2 (OSRAM) |
| MX (1) | MX2019011061A (OSRAM) |
| SG (1) | SG11201908598PA (OSRAM) |
| WO (1) | WO2018167269A1 (OSRAM) |
| ZA (1) | ZA201906269B (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11807622B2 (en) | 2019-01-30 | 2023-11-07 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
| US10689360B1 (en) * | 2019-01-30 | 2020-06-23 | Insilico Medicine Ip Limited | TLR inhibitors |
| GB201905780D0 (en) | 2019-04-25 | 2019-06-05 | La Thangue Nicholas | Cancer therapy |
| EP3980406A4 (en) * | 2019-06-06 | 2023-06-28 | Aligos Therapeutics, Inc. | Heterocyclic compounds |
| CN110950841A (zh) * | 2019-11-22 | 2020-04-03 | 济南大学 | 一类新型三唑类化合物的合成及应用 |
| WO2021126728A1 (en) * | 2019-12-17 | 2021-06-24 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| KR20230012041A (ko) * | 2020-06-02 | 2023-01-25 | 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 | 3,4-디하이드로이소퀴놀린계 화합물 및 그 사용 |
| AU2021289665A1 (en) | 2020-06-10 | 2022-12-15 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| CN115768769B (zh) * | 2020-06-30 | 2024-10-22 | 南京再明医药有限公司 | 四氢异喹啉类化合物及其用途 |
| KR20230047458A (ko) | 2020-09-04 | 2023-04-07 | 이노웨이스톤 테라퓨틱스 리미티드 | 항종양 활성을 갖는 화합물 및 이의 용도 |
| WO2022175747A1 (en) | 2021-02-19 | 2022-08-25 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| MX2023009685A (es) | 2021-02-19 | 2023-10-30 | Sudo Biosciences Ltd | Inhibidores de tyk2 y sus usos. |
| EP4339193A4 (en) | 2021-05-13 | 2025-06-04 | Innovstone Therapeutics Limited | Compound having anti-tumor activity and use thereof |
| GB202108383D0 (en) | 2021-06-11 | 2021-07-28 | Argonaut Therapeutics Ltd | Compounds useful in the treatment or prevention of a prmt5-mediated disorder |
| CA3224494A1 (en) | 2021-07-09 | 2023-01-12 | Koen Vandyck | Anti-viral compounds |
| WO2023043816A1 (en) | 2021-09-17 | 2023-03-23 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| GB202117230D0 (en) | 2021-11-29 | 2022-01-12 | Argonaut Therapeutics Ltd | Peptide vaccine |
| CN116867491A (zh) * | 2021-12-08 | 2023-10-10 | 石药集团中奇制药技术（石家庄）有限公司 | 3,4-二氢异喹啉类化合物的盐及其应用 |
| CN118475569A (zh) * | 2021-12-30 | 2024-08-09 | 南京再明医药有限公司 | 四氢异喹啉类化合物的可药用盐、晶型及其用途 |
| CN118488841A (zh) * | 2022-01-06 | 2024-08-13 | 南京再明医药有限公司 | Prmt5抑制剂和抗癌治疗剂的组合 |
| GB202203588D0 (en) | 2022-03-15 | 2022-04-27 | Argonaut Therapeutics Ltd | Cancer diagnostic |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016505000A (ja) * | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| US9604930B2 (en) | 2012-12-21 | 2017-03-28 | Epizyme, Inc. | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof |
| EP2935242A2 (en) * | 2012-12-21 | 2015-10-28 | Epizyme, Inc. | Methods of inhibiting prmt5 |
| JP2016505002A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用 |
| US20170210751A1 (en) * | 2014-06-25 | 2017-07-27 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| EP3160477A4 (en) * | 2014-06-25 | 2018-07-04 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| WO2016034673A1 (en) | 2014-09-03 | 2016-03-10 | Ctxt Pty Ltd | Tetrahydroisoquinoline derived prmt5-inhibitors |
| GB201415573D0 (en) | 2014-09-03 | 2014-10-15 | Cancer Therapeutics Crc Pty Ltd | Compounds |
-
2017
- 2017-03-17 GB GBGB1704327.4A patent/GB201704327D0/en not_active Ceased
-
2018
- 2018-03-16 AU AU2018235139A patent/AU2018235139A1/en not_active Abandoned
- 2018-03-16 MX MX2019011061A patent/MX2019011061A/es unknown
- 2018-03-16 US US16/494,532 patent/US11485731B2/en active Active
- 2018-03-16 WO PCT/EP2018/056663 patent/WO2018167269A1/en not_active Ceased
- 2018-03-16 KR KR1020197030311A patent/KR102616970B1/ko active Active
- 2018-03-16 SG SG11201908598P patent/SG11201908598PA/en unknown
- 2018-03-16 IL IL269354A patent/IL269354B2/en unknown
- 2018-03-16 CA CA3056724A patent/CA3056724A1/en active Pending
- 2018-03-16 EP EP18714178.3A patent/EP3596061B1/en active Active
- 2018-03-16 CN CN201880032332.4A patent/CN110650950B/zh active Active
- 2018-03-16 JP JP2019571788A patent/JP7211982B2/ja active Active
-
2019
- 2019-09-23 ZA ZA2019/06269A patent/ZA201906269B/en unknown
-
2022
- 2022-04-11 AU AU2022202389A patent/AU2022202389B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020510091A5 (OSRAM) | ||
| JP2019529490A5 (OSRAM) | ||
| JP2019527203A5 (OSRAM) | ||
| JP2018522879A5 (OSRAM) | ||
| JP2018536634A5 (OSRAM) | ||
| JP2014501766A5 (OSRAM) | ||
| JP2017508789A5 (OSRAM) | ||
| JP2016505637A5 (OSRAM) | ||
| JP2016518437A5 (OSRAM) | ||
| JP2017523169A5 (OSRAM) | ||
| JP2016518328A5 (OSRAM) | ||
| JP2012522847A5 (OSRAM) | ||
| JP2019510810A5 (OSRAM) | ||
| JP2019524883A5 (OSRAM) | ||
| JP2019518766A5 (OSRAM) | ||
| JP2020527173A5 (OSRAM) | ||
| JP2016121196A5 (OSRAM) | ||
| RU2012109554A (ru) | Лиганды сигма-рецепторов для предупреждения или лечения боли, вызванной химиотерапией | |
| JP2016537382A5 (OSRAM) | ||
| JP2012524056A5 (OSRAM) | ||
| RU2018102372A (ru) | Новые аминокислотные производные, способ их получения и фармацевтические композиции, содержащие их | |
| JP2014521688A5 (OSRAM) | ||
| JP2019530699A5 (OSRAM) | ||
| JP2017508782A5 (OSRAM) | ||
| RU2016134751A (ru) | Соединения |